Nicht ossifizierendes Knochenfibrom und benigne fibröse Histiozytome: ein Update

• Literatur

• 1 Baumhoer D, Kovac M, Sperveslage J. et al. Activating mutations in the MAP-kinase pathway define non-ossifying fibroma of bone. J Pathol 2019; 248: 116-122
• 2 Anglesio MS, Papadopoulos N, Ayhan A. et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med 2017; 376: 1835-1848
• 3 Nikolaev SI, Vetiska S, Bonilla X. et al. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. N Engl J Med 2018; 378: 250-261
• 4 Kuznetsov SA, Cherman N, Riminucci M. et al. Age-dependent demise of GNAS-mutated skeletal stem cells and “normalization” of fibrous dysplasia of bone. J Bone Miner Res 2008; 23: 1731-1740
• 5 Gomes CC, Gayden T, Bajic A. et al. TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nat Commun 2018; 9: 45-72
• 6 Matsuno T. Benign fibrous histiocytoma involving the ends of long bone. Skeletal Radiol 1990; 19: 561-566